The North America EGFR-TKI for Advanced NSCLC Market is expected to maintain strong growth through 2034, supported by advances in precision oncology, increasing adoption of biomarker-driven treatment approaches, and continued innovation in targeted therapies for EGFR-mutated non-small cell lung cancer. The region benefits from a well-established oncology research ecosystem, advanced molecular...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek